Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anakinra for hereditary autoinflammatory disease with MEFV S242R mutation
2015-004292-69Phase 4Completed
- Sponsor
- UZ Leuven
- Start
- Dec 2015
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of anakinra in Hereditary systemic autoinflammatory diseases (SAIDs) and Pyrin-associated autoinflammatory disease with neutrophilic dermatosis (PAAND), sponsored by UZ Leuven. Primary endpoint: Safety and inflammation parameters over time. Started Dec 2015; status: completed.
02
Drugs
anakinra
03
Conditions
Hereditary systemic autoinflammatory diseases (SAIDs)Pyrin-associated autoinflammatory disease with neutrophilic dermatosis (PAAND)
Beyond the preview
Go deeper on 2015-004292-69.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-004292-69.